UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models

JNCI : Journal of the National Cancer Institute, 2010-05, Vol.102 (10), p.680-691

2010

Volltextzugriff (PDF)

Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies

Cancer treatment reviews, 2012-10, Vol.38 (6), p.708-714

2012

Volltextzugriff (PDF)

Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing

Modern pathology, 2019-12, Vol.32 (12), p.1823-1833

2019

Volltextzugriff (PDF)

Evaluation of a comprehensive geriatric assessment tool in geriatric cancer patients undergoing adjuvant chemotherapy: a pilot study

Supportive care in cancer, 2019-05, Vol.27 (5), p.1871-1877

2019

Volltextzugriff (PDF)

A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer

Current oncology (Toronto), 2024-08, Vol.31 (8), p.4531-4545

2024

Volltextzugriff (PDF)

Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer?

Breast cancer research and treatment, 2008-04, Vol.108 (3), p.307-317

2008

Volltextzugriff (PDF)

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases

Cancer, 2010-01, Vol.116 (2), p.284-291

2010

Volltextzugriff (PDF)

Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?

Critical reviews in oncology/hematology, 2009-10, Vol.72 (1), p.56-64

2009

Volltextzugriff (PDF)

Approach to inflammatory breast cancer

Canadian family physician, 2009-01, Vol.55 (1), p.25-31

2009

Volltextzugriff (PDF)

Delayed hypersensitivity reactions to multiple aromatase inhibitors followed by successful desensitization to letrozole

Annals of allergy, asthma, & immunology, 2021-09, Vol.127 (3), p.378-379

2021

Volltextzugriff (PDF)

Abstract OT1-07-01: MRI screening versus symptom-directed surveillance for brain metastases among patients with triple negative or HER2+ metastatic breast cancer: A pilot study (nct03881605)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-07-01-OT1-07-01

2022

Volltextzugriff (PDF)

Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-01-01-OT1-01-01

2022

Volltextzugriff (PDF)

Underestimation of risk by Gail model extends beyond women with atypical hyperplasia

Journal of clinical oncology, 2009-03, Vol.27 (9), p.1526; author reply 1527-1526

2009

Volltextzugriff (PDF)

Chemotherapy Dose-dense treatment for triple-negative breast cancer

Nature reviews. Clinical oncology, 2010-02, Vol.7 (2), p.79-80

2010

Volltextzugriff (PDF)

Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD8-01-PD8-01

2022

Volltextzugriff (PDF)

Abstract 4798: MRI screening for brain metastases (BrM) versus SYMptom-directed brain imaging for patients with triple negative (TN) or HER2+ metastatic breast cancer (MBC): An ad-hoc interim analysis of a randomized phase II pilot study

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.4798-4798

2024

Volltextzugriff (PDF)

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D 3 in breast cancer patients with bone metastases

Cancer, 2010-01, Vol.116 (2), p.284-291

2010

Volltextzugriff (PDF)

Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.GS01-12-GS01-12

2024

Volltextzugriff (PDF)

Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer

Cancer treatment reviews, 2010-08, Vol.36 (5), p.410-415

2010

Volltextzugriff (PDF)

Defining ovarian failure in amenorrheic young breast cancer patients

Breast (Edinburgh), 2010-12, Vol.19 (6), p.545-548

2010

Volltextzugriff (PDF)

Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials

Supportive care in cancer, 2011-03, Vol.19 (3), p.315-322

2011

Volltextzugriff (PDF)

Amenorrhoea, menopause, and endocrine therapy for breast cancer

BMJ. British medical journal (International ed.), 2010-01, Vol.340 (7736), p.48

International edition, 2010

Volltextzugriff (PDF)

Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1919; author reply 1920-1919

2009

Volltextzugriff (PDF)

Dose-dense treatment for triple-negative breast cancer

Nature reviews. Clinical oncology, 2010-02, Vol.7 (2), p.79-80

2010

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

ThemaAntineoplastic Combined Chemotherapy Protocols - Therapeutic Use

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(29)

Publikationsform

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models

Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies

Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing

Evaluation of a comprehensive geriatric assessment tool in geriatric cancer patients undergoing adjuvant chemotherapy: a pilot study

A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer

Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer?

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases

Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?

Approach to inflammatory breast cancer

Delayed hypersensitivity reactions to multiple aromatase inhibitors followed by successful desensitization to letrozole

Abstract OT1-07-01: MRI screening versus symptom-directed surveillance for brain metastases among patients with triple negative or HER2+ metastatic breast cancer: A pilot study (nct03881605)

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial)

Underestimation of risk by Gail model extends beyond women with atypical hyperplasia

Chemotherapy Dose-dense treatment for triple-negative breast cancer

Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis

Abstract 4798: MRI screening for brain metastases (BrM) versus SYMptom-directed brain imaging for patients with triple negative (TN) or HER2+ metastatic breast cancer (MBC): An ad-hoc interim analysis of a randomized phase II pilot study

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D 3 in breast cancer patients with bone metastases

Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer

Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer

Defining ovarian failure in amenorrheic young breast cancer patients

Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials

Amenorrhoea, menopause, and endocrine therapy for breast cancer

Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?

Dose-dense treatment for triple-negative breast cancer

Aktive Filter

Suchergebnisse filtern